Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

International Journal of Antimicrobial Agents

Volumn 24, Issue 6, 2004, Pages 567-571

  Fritsche, Thomas R ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Glycylcyclines; Resistance; Staphylococcus aureus; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; HOSPITAL INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OXACILLIN; STAPHYLOCOCCUS AUREUS;

EID: 8844239275     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.07.007     Document Type: Article

References (21)

1. S.E. Cosgrove, G. Sakoulas, and E.N. Perencevich Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin Infect Dis 36 2003 53 59
2. D.J. Diekema, M.A. Pfaller, F.J. Schmitz and the SENTRY Participants Group Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin Infect Dis 15 Suppl. 2 2001 S114 32
3. T.S. Naimi, K.H. LeDell, and D.J. Boxrud Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998 Clin Infect Dis 33 2001 990 996
4. K. Okuma, K. Iwakawa, and J.D. Turnidge Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community J Clin Microbiol 40 2002 4289 4294
5. F. Vandenesch, T. Naimi, and M.C. Enright Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence Emerg Infect Dis 9 2003 978 984
6. D.M. Livermore Bacterial resistance: origins, epidemiology, and impact Clin Infect Dis 36 Suppl 1 2003 S11 S23
7. F.C. Tenover, L.M. Weigel, and P.C. Appelbaum Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania Antimicrob Agents Chemother 48 2004 275 280
8. A. Canu, and R. Leclercq Overcoming bacterial resistance by dual target inhibition: the case of streptogramins Curr Drug Targets Infect Disord 1 2001 215 225
9. A.H. Mutnick, V. Enne, and R.N. Jones Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program Ann Pharmacother 37 2003 769 774
10. K.A. Ruggero, L.K. Schroeder, and P.C. Schreckenberger Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs Diagn Microbiol Infect Dis 47 2003 511 513
11. E. Cercenado, S. Cercenado, and J.A. Gomez In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides J Antimicrob Chemother 52 2003 138 139
12. A.C. Gales, and R.N. Jones Antimicrobial activity and spectrum of the new glycylcycline, GAR-936, tested against 1,203 recent clinical bacterial isolates Diagn Microbiol Infect Dis 36 2000 19 36
13. R. Patel, M.S. Rouse, and K.E. Piper In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae Diagn Microbiol Infect Dis 38 2002 177 179
14. P.J. Petersen, N.V. Jacobus, and W.J. Weiss In vitro and in vivo antibacterial activities of a new glycylcycline, the 9-t-butyglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 1999 738 744
15. J. Bergeron, M. Ammirati, and D. Danley Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection Antimicrob Agents Chemother 40 1996 2226 2228
16. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 6th ed. Document M7-A6. NCCLS, Wayne, PA, 2003.
17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 14th informational supplement. Document M100-S14. NCCLS, Wayne, PA, 2004.
18. R. Jones Disk diffusion susceptibility test development for the new glycylcycline, GAR-936 Diagn Microbiol Infect Dis 35 1999 249 252
19. C. Betriu, I. Rodriguz-Avial, and B.A. Sanchez In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain Antimicrob Agents Chemother 46 2002 892 895
20. H.W. Boucher, C.B. Wennersten, and G.M. Eliopoulos In vitro activities of the glycylcycline GAR-936 against Gram-positive bacteria Antimicrob Agents Chemother 44 2002 2225 2229
21. M.D. Kitzis, A. Ly, and F.W. Goldstein In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae Antimicrob Agents Chemother 48 2004 366 367